AVT03 is a biosimilar candidate to the reference products Prolia and Xgeva (denosumab).

Prolia and Xgeva are used to treat conditions including osteoporosis in postmenopausal women and to prevent skeletal-related events in adults with advanced cancers.

The agreement will leverage Dr Reddy’s global commercial reach and Alvotech’s biosimilar development expertise.

Alvotech will be tasked with the development and manufacturing of AVT03.